Drug Type AAV based gene therapy |
Synonyms recombinant adeno-associated virus vector-based gene therapy comprising a recombinant AAV genome encoding human ALDH5A1, GAL 005, GAL005 |
Target |
Action modulators |
Mechanism ALDH5A1 modulators(aldehyde dehydrogenase 5 family member A1 modulators) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Succinic Semialdehyde Dehydrogenase Deficiency | Preclinical | United States | 01 Oct 2025 |





